揭示极其有害的IRAK4变体及其对IRAK4抑制剂有效性的潜在影响
Mohammed Y Behairy1, Refaat A Eid2, Hassan M Otifi2
1Department of Microbiology and Immunology, Faculty of Pharmacy, University of Sadat City, Sadat City 32897, Egypt.
Journal of personalized medicine
|December 23, 2023
概括
这项研究确定了IRAK4基因中的十种有害的误解变异,影响蛋白质功能和稳定性. 这些IRAK4基因变异影响抑制剂的有效性,有助于疾病预测.
科学领域:
- 遗传学和分子生物学
- 生物信息学和计算生物学
- 结构生物学 结构生物学
背景情况:
- 介素-1-受体相关激酶4 (IRAK4) 对于通类受体 (TLR) 信号传递至关重要.
- 伊拉克4功能障碍与传染病,免疫系统疾病和癌症有关.
- 在IRAK4的遗传变异与各种病理有关.
研究的目的:
- 使用生物信息学工具全面分析IRAK4误解变体.
- 评估单核酸多态 (SNP) 对IRAK4功能,稳定性和结构的影响.
- 为了评估这些变体对IRAK4抑制剂结合的影响.
主要方法:
- 利用各种生物信息学工具分析IRAK4 SNPs对蛋白质功能,稳定性和结构的影响.
- 研究的残留物位置,保存状况和二次/3D结构.
- 采用分子对接和结构生物学来评估对IRAK4抑制剂 (HG-12-6) 的影响.
主要成果:
- 在IRAK4.4的高度保护区域中确定了10种有害的误解变异.
- 在几个变体中观察到蛋白质稳定性,二次结构 (L318S/F) 和3D结构的变化.
- 证明鉴定到的SNP变异会对IRAK4抑制剂HG-12-6的结合亲和力产生负面影响,这是由于结合位相互作用的改变.
结论:
- 有害的IRAK4变体显著影响蛋白质结构,稳定性和抑制剂的有效性.
- 这种分析为预测IRAK4相关疾病和了解变异对药物有效性的影响提供了基础.
- 这些发现强调了在针对IRAK4.4的治疗策略中考虑遗传变异的重要性.
相关概念视频
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
141
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168


